Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
View Patent ↗The present application is directed to compositions and methods for mechanically controlling the bleeding of bone. The compositions comprise in intimate admixture the following Components 1, 2 and 3: (1) a finely powdered, carboxylic acid salt comprising a carboxylate anion and a metallic cation, (2) a composition comprising pyrrolidone or an N-alkyl pyrrolidone wherein alkyl is a C1-C12 alkyl radical and an optional, biocompatible liquefying agent if the composition is in solid form at room temperature, and (3) an optional analgesic, wherein the analgesic is present in a free base and salt form.
1. A composition comprising in intimate admixture the following Components 1, 2 and 3 wherein
Component 1 is a finely powdered, carboxylic acid salt comprising a carboxylate anion and a metallic cation,
Component 2 is a composition comprising pyrrolidone or an N-alkyl pyrrolidone wherein alkyl is a C 1 -C 12 alkyl radical and an optional, biocompatible liquefying agent for Component 2 when Component 2 is in solid form at room temperature, and
Component 3 is an optional analgesic, wherein the analgesic is present in a free base and salt form.
2. The composition of claim 1 wherein said composition is body absorbable.
3. The composition of claim 2 wherein the carboxylate anion of Component 1 is selected from saturated or unsaturated carboxylic acids containing about 6 to 22 carbon atoms.
4. The composition of claim 3 wherein the carboxylate salt cation of Component 1 is calcium, magnesium, zinc, aluminum, or barium or mixtures thereof.
5. The composition of claim 4 wherein the carboxylate anion of Component 1 is an aliphatic acid selected from caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, and intervening homologs thereof.
6. The composition of claim 5 wherein the carboxylate anion of Component 1 is stearic acid.
7. The composition of claim 5 wherein the carboxylate anion of Component 1 is palmitic acid.
8. The composition of claim 6 wherein the carboxylate salt cation of Component 1 is calcium.
9. The composition of claim 7 wherein the carboxylate salt cation of Component 1 is aluminum.
10. The composition of claim 2 wherein Component 2, comprises N-methylpyrrolidone.
11. The composition of claim 8 wherein Component 2 comprises N-methylpyrrolidone.
12. The composition of claim 9 wherein Component 2 comprises N-methylpyrrolidone.
13. A composition comprising in intimate admixture the following Components 1, 2 and 3 wherein
Component 1 is at least one of a finely powdered material selected from the group consisting of:
a) a material comprising a member selected from the group consisting of demineralized bone matrix, mineralized bone matrix, hydroxyapatite, an insoluble absorbable collagen, gelatin derived from collagens, a monosaccharide, and a polysaccharide, b) a polylactide, c) a polyglycolide, d) copolymers of lactide and glycolide, e) a polydioxanone, f) a polycaprolactone, g) copolymers of dioxanone and of caprolactone and of trimethylene carbonate, h) a glass, and i) a bioactive glass
Component 2 is a composition comprising pyrrolidone or an N-alkyl pyrrolidone wherein alkyl is a C 1 -C 12 alkyl radical, and an optional, biocompatible, liquefying agent for Component 2 when Component 2 is in solid form at room temperature, and
Component 3 is an optional analgesic, wherein the analgesic is present in a free base and salt form.
14. The composition of claim 13 wherein said composition is body-absorbable.
15. The composition of claim 14 wherein Component 1 comprises DBM.
16. The composition of claim 14 wherein Component 1 comprises hydroxyapatite.
17. The composition of claim 14 wherein Component 1 comprises collagen.
18. The composition of claim 14 wherein Component 1 comprises gelatin.
19. The composition of claim 14 wherein, Component 1 comprises a polylactide, a polyglycolide, or a copolymer of lactide and glycolide.
20. The composition of claim 14 wherein Component 1 comprises dioxanone, caprolactone, and copolymers of dioxanone and of caprolactone and of trimethylene carbonate.
21. The composition of claim 14 wherein Component 1 comprises an absorbable phosphorus oxide glass.
22. The composition of claim 14 wherein Component 1 comprises a bioactive glass.
23. The composition of claim 14 wherein Component 1 comprises a monosaccharide or a polysaccharide.
24. The composition of claim 14 wherein Component 2, comprises N-methylpyrrolidone.
25. A package comprising the composition of claim 2 wherein said composition is amorphous or in a generally rounded form or in a generally parallelepiped form or in the form of a cream or paste or in the form of the container in which it is contained, wherein said composition is sealed in an aseptic barrier package, and is sterile or sterilizable.
26. The package of claim 25 wherein the package comprises a plunger or applicator whereby said composition is expellable from said package by the application of mechanical pressure applied to the plunger or applicator.
27. The package of claim 25 wherein the package comprises a squeezable, deformable tube having an openable exit port whereby said composition is expellable from said tube by the application of mechanical pressure thereto.
28. The composition of claim 25 wherein said composition is sterile.
29. A package comprising the composition of claim 14 wherein said composition is amorphous or in a generally rounded form or in a generally parallelepiped form or in the form of a cream or paste or in the form of the container in which it is contained, wherein said composition is sealed in an aseptic barrier package, and is sterile or sterilizable.
30. The package of claim 29 wherein the package comprises a plunger or applicator whereby said composition is expellable from said package by the application of mechanical pressure applied to the plunger or applicator.
31. The package of claim 29 wherein the package comprises a squeezable, deformable tube having an openable exit port whereby said composition is expellable from said tube by the application of mechanical pressure thereto.
32. The composition of claim 29 wherein said composition is sterile.
33. A method for mechanically controlling the bleeding of bone which comprises applying an effective amount of the composition of claim 2 to the affected area.
34. A method for mechanically controlling the bleeding of bone which comprises applying an effective amount of the composition of claim 14 to the affected area.
35. The composition of claim 1 wherein said composition is sterile.
36. The composition of claim 13 wherein said composition is sterile.
37. The composition of claim 1 comprising Component 3, wherein the analgesic is selected from the group consisting of benzocaine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocalne, procaine, chloroprocaine, etidocaine, tetracaine, xylocalne, and propivacaine.
38. The composition of claim 37 , wherein the analgesic is lidocaine.
39. The composition of claim 37 , wherein the salt form is a hydrohalide.
40. The composition of claim 39 wherein the hydrohalide is selected from the group consisting of hydrochloride and hydrobromide.
41. The composition of claim 38 , wherein the free base form is lidocaine free base.
42. The composition of claim 39 , wherein the salt form is lidocaine hydrochloride.
43. The composition of claim 13 comprising Component 3, wherein the analgesic is selected from the group consisting of benzocaine, bupivacaine, dibucaine, lidocaine, mepivacaine, prilocalne, procaine, chloroprocaine, etidocaine, tetracaine, xylocaline, and propivacaine.
44. The composition of claim 43 , wherein the analgesic is lidocaine.
45. The composition of claim 43 , wherein the salt form is a hydrohalide.
46. The composition of claim 45 wherein the hydrohalide is selected from the group consisting of hydrochloride and hydrobromide.
47. The composition of claim 44 , wherein the free base form is lidocaine free base.
48. The composition of claim 46 , wherein the salt form is lidocaine hydrochloride.